Publisher
Springer Science and Business Media LLC
Reference65 articles.
1. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017. https://www.who.int. Accessed 21 Dec 2020.
2. Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations. Drugs. 2018;78(1):65–98.
3. Tabak YP, Sung A, Ye G, et al. Attributable burden in patients with carbapenem-nonsusceptible gram-negative respiratory infections. PLoS ONE. 2020;15(2):e0229393.
4. McCann E, Srinivasan A, DeRyke C, et al. Carbapenem-nonsusceptible gram-negative pathogens in ICU and non-ICU settings in US hospitals in 2017: a multicenter study. Open Forum Infect Dis. 2018;5(10):241.
5. Tabak YP, Sung AH, Ye G, et al. Attributable clinical and economic burden of carbapenem-non-susceptible gram-negative infections in patients hospitalized with complicated urinary tract infections. J Hosp Infect. 2019;102(1):37–44.
Cited by
59 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献